Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bellerophon Ther Com (BLPH)

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,452
  • Shares Outstanding, K 9,506
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,730 K
  • 60-Month Beta -0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.26
Trade BLPH with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.67
  • Number of Estimates 3
  • High Estimate -0.61
  • Low Estimate -0.74
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +20.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.71 +11.86%
on 09/15/21
4.38 -5.25%
on 08/31/21
+0.12 (+2.98%)
since 08/24/21
3-Month
3.66 +13.39%
on 08/23/21
5.75 -27.83%
on 06/28/21
-1.10 (-20.95%)
since 06/24/21
52-Week
3.66 +13.39%
on 08/23/21
10.43 -60.21%
on 10/05/20
-5.17 (-55.47%)
since 09/24/20

Most Recent Stories

More News
Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that...

BLPH : 4.15 (+4.01%)
Bellerophon Therapeutics: Q2 Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Thursday reported a loss of $3.4 million in its second quarter.

BLPH : 4.15 (+4.01%)
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a...

BLPH : 4.15 (+4.01%)
Walgreens (WBA) to Report Q3 Earnings: What's in Store?

Faster adoption of digital health and improved business environment are expected to have contributed to Walgreens' (WBA) third-quarter performance.

HSIC : 78.10 (+0.64%)
WBA : 48.31 (-0.31%)
BLPH : 4.15 (+4.01%)
BNTX : 333.48 (-5.53%)
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

BIIB : 291.71 (-0.51%)
RGEN : 323.26 (-0.29%)
BLPH : 4.15 (+4.01%)
BNTX : 333.48 (-5.53%)
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status

VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

GSK : 38.39 (-2.41%)
RGEN : 323.26 (-0.29%)
BLPH : 4.15 (+4.01%)
VBIV : 3.30 (-4.62%)
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel

Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

ARNA : 60.08 (-1.64%)
RGEN : 323.26 (-0.29%)
BLPH : 4.15 (+4.01%)
AKRO : 23.73 (-1.62%)
Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data

Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.

BLPH : 4.15 (+4.01%)
AKRO : 23.73 (-1.62%)
LEGN : 47.20 (-0.74%)
CGEM : 23.05 (-2.62%)
Bellerophon to Present at the Jefferies Virtual Healthcare Conference

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that...

BLPH : 4.15 (+4.01%)
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the...

BLPH : 4.15 (+4.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton,...

See More

Key Turning Points

3rd Resistance Point 4.42
2nd Resistance Point 4.30
1st Resistance Point 4.23
Last Price 4.15
1st Support Level 4.04
2nd Support Level 3.92
3rd Support Level 3.85

See More

52-Week High 10.43
Fibonacci 61.8% 7.84
Fibonacci 50% 7.04
Fibonacci 38.2% 6.25
Last Price 4.15
52-Week Low 3.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar